KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2025 value amounting to 0.08%.

  • Alnylam Pharmaceuticals' Return on Capital Employed rose 1500.0% to 0.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.08%, marking a year-over-year increase of 1500.0%. This contributed to the annual value of 0.06% for FY2024, which is 400.0% up from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' Return on Capital Employed stood at 0.08%, which was up 1500.0% from 0.06% recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Return on Capital Employed registered a high of 0.08% during Q3 2025, and its lowest value of 0.32% during Q2 2023.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.23% (2022), whereas its average is 0.16%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first soared by 3500bps in 2024, then tumbled by -900bps in 2025.
  • Alnylam Pharmaceuticals' Return on Capital Employed (Quarter) stood at 0.25% in 2021, then dropped by -14bps to 0.28% in 2022, then skyrocketed by 65bps to 0.1% in 2023, then skyrocketed by 41bps to 0.06% in 2024, then soared by 244bps to 0.08% in 2025.
  • Its last three reported values are 0.08% in Q3 2025, 0.06% for Q2 2025, and 0.04% during Q1 2025.